Xeris Biopharma Holdings (XERS) Net Cash Flow (2020 - 2026)

Xeris Biopharma Holdings' Net Cash Flow history runs 7 years deep, the most recent figure standing at $708000.0 for Q1 2026.

• Quarterly Net Cash Flow rose 105.37% year-over-year to $708000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $53.2 million (up 1322.61% YoY) and the FY2025 annual result came in at $39.3 million, up 866.07% from the prior year.
• Net Cash Flow was $708000.0 for Q1 2026 at Xeris Biopharma Holdings, down from $19.4 million in the prior quarter.
• Across five years, Net Cash Flow topped out at $42.2 million in Q4 2022 and bottomed at -$71.0 million in Q1 2023.
• A 5-year average of $2.9 million and a median of $708000.0 in 2026 frame the typical range for Net Cash Flow.
• Annual changes were most pronounced in 2023 — Net Cash Flow plunged 294.47% — and 2024, when it jumped 5751.85%.
• Xeris Biopharma Holdings' Net Cash Flow stood at $42.2 million in 2022, then sank by 49.99% to $21.1 million in 2023, then slumped by 41.3% to $12.4 million in 2024, then surged by 56.95% to $19.4 million in 2025, then sank by 96.36% to $708000.0 in 2026.
• Business Quant data shows XERS's Net Cash Flow at $708000.0 in Q1 2026, $19.4 million in Q4 2025, and $32.2 million in Q3 2025.